Studies with Intra-Articular Hyaluronic Acid Injection in Ankle Osteoarthritis
| Author, year | Patient (n) | Mean follow-up (mo) | OA grade | Hyaluronic acid |
Injection times (interval) | Clinical outcomes |
Complication (cases) |
|---|---|---|---|---|---|---|---|
| Luciani et al.20), 2008 | 21 | 18 | K-L 2 | Synvisc®, 2 mL, 6,000 kDa, 20 mg | 3 (weekly) | AOS pain 44.5 → 34.4 | Arthralgia (11) |
| Mei-Dan et al.21), 2010 | 16 | 7 | K-L 2~4 | Adant®, 2.5 mL, 600~1,200 kDa, 25 mg | 5 (weekly) | VAS 5.3 → 3.1 | Arthralgia (1) |
| Sun et al.19), 2011 | 46 | 6 | K-L 2~3 | Hyalgan®, 2 mL, 500~730 kDa, 20 mg | 3 (weekly) | AOFAS 60.5 → 76.7 AOS 5.5 → 3.2 |
Arthralgia (3) Pruritis (1) |
| Murphy et al.17), 2017 | 50 | 12 | NR | Suplasyn®, 2 mL, 500~1,000 kDa, 20 mg | 3 (2 weeks) | FAOS 48 → 78 | None |
| Younger et al.15), 2019 | 37 | 6.5 | K-L 2~3 | Durolane®, 1 mL, 105 kDa, 20 mg | 1 (single) | VAS 51.5 → 37.1 | Arthralgia (3) |
| Lee et al.2), 2022 | 37 | 13.8 | Takakura 2~3 | Hyruan Plus®, 2 mL, 3,000 kDa, 10 mg | 3 (weekly) | AOS pain 32.9 → 27.1 AOFAS 73.0 → 83.0 VAS 4.0 → 3.0 |
Arthralgia (3) Ankle swelling (2) Pain or numbness (2) |
OA: osteoarthritis, K-L: Kellgren-Lawrence, NR: not reported, AOS: ankle osteoarthritis scale, VAS: visual analog scale, AOFAS: American Orthopedic Foot and Ankle Society ankle-hindfoot score, FAOS: foot and ankle outcomes score.
*Product name, volume, molecular weight, amount of hyaluronic acid.
†Change of outcomes statistically significant.
